Sing Medical – Trades at a 13-month low price despite posting record 1HFY21 results (3 Feb 22)

Dear all On 29 Dec 2020, I have published a write-up on Sing Medical (“SMG”) where I outlined that the risk reward on SMG seems favourable at $0.315, given a potential share transaction scenario (click HERE). Since 29 Dec, SMG rose approximately 32% to trade $0.415 – 0.420 on several occasions in Feb 2021. Subsequently, it dropped sharply in Apr 2021 when it announced that the potential share transaction has lapsed. Fast forward to 31 Jan 2022 and SMG closed at a 13-month low at $0.290. This is notwithstanding its sterling record 1HFY21 results announced in Aug last year where […]

My thoughts on Sing Medical Group’s possible share transaction (29 Dec 20)

Dear all Sing Medical Group (“SMG”) announced on 18 Dec 20 that the Company is currently in discussions with a third party regarding a possible transaction involving the Company’s shares. The discussions are preliminary and there is no certainty or assurance that such discussions will progress beyond the current stage or that any transaction will materialise as a result of such discussions.   Why am I interested in SMG? My personal view is that at $0.315, given a potential share transaction scenario, the risk reward seems favourable. Please refer to my basis and the risks as highlighted below: 1) Past […]

Sembmarine – leveraged play among oil companies (29 Apr 19)

Dear all, This week, Sembcorp marine (“SMM”) caught my attention amid positive industry reports and its strengthening chart. I have started to accumulate SMM with my usual take profit target of a few bids, if any. Let’s look at the basis, and importantly, the investment risks.   Basis a) Analysts are turning positive Based on Figure 1 below, average analyst target price for SMM is around $1.93, representing a potential capital appreciation of around 12% from the current price $1.72. It is noteworthy that JP Morgan has turned positive on SMM last month with a target price of $2.10, after […]